Title:
【発明の名称】グルタメート作用性伝達における異常を処置するための2-アダマンタンメタンアミン化合物
Document Type and Number:
Japanese Patent JP2002535360
Kind Code:
A
Abstract:
The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.
More Like This:
Inventors:
Gilspie, roger john
Monk, Nathaniel Julius Thomas
Bird, Andrew James
Ward, simon edward
Monk, Nathaniel Julius Thomas
Bird, Andrew James
Ward, simon edward
Application Number:
JP2000595674A
Publication Date:
October 22, 2002
Filing Date:
January 26, 2000
Export Citation:
Assignee:
Bernaris Research Limited
International Classes:
A61K31/13; A61K31/135; A61K31/137; A61K31/381; A61K31/41; A61K31/4245; A61K31/433; A61P1/14; A61P3/10; A61P9/00; A61P9/10; A61P15/06; A61P19/08; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P25/32; A61P25/36; A61P27/02; A61P27/06; A61P29/00; A61P31/18; A61P31/22; A61P41/00; A61P43/00; C07C211/17; C07C211/27; C07C211/29; C07C215/28; C07C217/60; C07D333/20; (IPC1-7): A61K31/137; A61K31/13; A61K31/381; A61P1/14; A61P3/10; A61P9/00; A61P9/10; A61P15/06; A61P19/08; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P25/32; A61P25/36; A61P27/02; A61P27/06; A61P29/00; A61P31/18; A61P31/22; A61P41/00; A61P43/00; C07C211/17; C07C211/27; C07C211/29; C07C215/28; C07D333/20
Domestic Patent References:
| JPH08501297A | 1996-02-13 |
Foreign References:
| DE1910560A1 | 1969-10-09 | |||
| DE2521894A1 | 1975-12-04 | |||
| EP0382251A2 | 1990-08-16 |
Other References:
JPN6010032442, Ｍａｄｄｅｒ Ａ．， ｅｔ ａｌ．, "Ｍｅｃｈａｎｉｓｍ ｏｆ ｅｓｔｅｒｉｆｉｃａｔｉｏｎ ｏｆ １，３−ｄｉｍｅｔｈｙｌａｍｉｎｏ ａｌｃｏｈｏｌｓ ｂｙ Ｎ−ａｃｅｔｙｌｉｍｉｄａｚｏｌｅ ｉｎ ａｃｅｔｏｎｉｔｒｉｌｅ ａｎｄ ｔ", Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ， Ｐｅｒｋｉｎ Ｔｒａｎｓａｃｔｉｏｎｓ ２, 1997, Ｎｏ． １２, ｐ． ２７８７−２７９３
JPN5002002941, ＣＨＡＫＲＡＢＡＲＴＩ Ｊ．Ｋ．， ｅｔ ａｌ, "Ａｄａｍａｎｔａｎｅａｌｋａｎａｍｉｎｅｓ ａｓ Ｐｏｔｅｎｔｉａｌ Ａｎｔｉｄｅｐｒｅｓｓａｎｔ ａｎｄ Ａｎｔｉ−Ｐａｒｋｉｎｓｏｎ Ａｇｅｎｔｓ", ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ, 197406, Ｖｏｌ． １７， Ｎｏ． ６, ｐ． ６０２−６０９
JPN6010032444, Ｋｏｒｎｈｕｂｅｒ Ｊ．， ｅｔ ａｌ．, "Ｅｆｆｅｃｔｓ ｏｆ ｔｈｅ １−ａｍｉｎｏ−ａｄａｍａｎｔａｎｅｓ ａｔ ｔｈｅ ＭＫ−８０１−ｂｉｎｄｉｎｇ ｓｉｔｅ ｏｆ ｔｈｅ ＮＭＤＡ−ｒｅｃｅｐｔｏｒ−ｇａｔｅｄ ｉｏｎ ｃｈａｎｎｅｌ", Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｏｌｏｇｙ： Ｍｏｌｅｃｕｌａｒ Ｐｈａｒｍａｃｏｌｏｇｙ, 1991, Ｖｏｌ． ２０６， Ｎｏ． ４, ｐ． ２９７−３００
JPN5002002942, ＰＯＲＴＥＲ Ｒ．Ｈ．Ｐ．， ｅｔ ａｌ．, "Ｒｅｇｉｏｎａｌ Ｖａｒｉａｔｉｏｎｓ ｉｎ ｔｈｅ Ｐｈａｒｍａｃｏｌｏｇｙ ｏｆ ＮＭＤＡ Ｒｅｃｅｐｔｏｒ Ｃｈａｎｎｅｌ Ｂｌｏｃｋｅｒｓ： Ｉｍｐｌｉｃａｔｉｏｎｓ ｆｏｒ Ｔｈｅｒａｐｅｕ", ＪＯＵＲＮＡＬ ＯＦ ＮＥＵＲＯＣＨＥＭＩＳＴＲＹ, 1995, Ｖｏｌ． ６４， Ｎｏ． ２, ｐ． ６１４−６２３
JPN5002002941, ＣＨＡＫＲＡＢＡＲＴＩ Ｊ．Ｋ．， ｅｔ ａｌ, "Ａｄａｍａｎｔａｎｅａｌｋａｎａｍｉｎｅｓ ａｓ Ｐｏｔｅｎｔｉａｌ Ａｎｔｉｄｅｐｒｅｓｓａｎｔ ａｎｄ Ａｎｔｉ−Ｐａｒｋｉｎｓｏｎ Ａｇｅｎｔｓ", ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ, 197406, Ｖｏｌ． １７， Ｎｏ． ６, ｐ． ６０２−６０９
JPN6010032444, Ｋｏｒｎｈｕｂｅｒ Ｊ．， ｅｔ ａｌ．, "Ｅｆｆｅｃｔｓ ｏｆ ｔｈｅ １−ａｍｉｎｏ−ａｄａｍａｎｔａｎｅｓ ａｔ ｔｈｅ ＭＫ−８０１−ｂｉｎｄｉｎｇ ｓｉｔｅ ｏｆ ｔｈｅ ＮＭＤＡ−ｒｅｃｅｐｔｏｒ−ｇａｔｅｄ ｉｏｎ ｃｈａｎｎｅｌ", Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｏｌｏｇｙ： Ｍｏｌｅｃｕｌａｒ Ｐｈａｒｍａｃｏｌｏｇｙ, 1991, Ｖｏｌ． ２０６， Ｎｏ． ４, ｐ． ２９７−３００
JPN5002002942, ＰＯＲＴＥＲ Ｒ．Ｈ．Ｐ．， ｅｔ ａｌ．, "Ｒｅｇｉｏｎａｌ Ｖａｒｉａｔｉｏｎｓ ｉｎ ｔｈｅ Ｐｈａｒｍａｃｏｌｏｇｙ ｏｆ ＮＭＤＡ Ｒｅｃｅｐｔｏｒ Ｃｈａｎｎｅｌ Ｂｌｏｃｋｅｒｓ： Ｉｍｐｌｉｃａｔｉｏｎｓ ｆｏｒ Ｔｈｅｒａｐｅｕ", ＪＯＵＲＮＡＬ ＯＦ ＮＥＵＲＯＣＨＥＭＩＳＴＲＹ, 1995, Ｖｏｌ． ６４， Ｎｏ． ２, ｐ． ６１４−６２３
Attorney, Agent or Firm:
Shusaku Yamamoto